- In December 2022, Sorrento Therapeutics, Inc. has obtained clearance from the U.S. FDA to commence clinical trials using its next-generation mRNA (STI-1557) vaccine targeting SARS-CoV-2 Omicron variants
- In July 2022, Byondis has received acceptance of the biologics license application by the U.S. FDA for Vic-Trastuzumab Duocarmazine (SYD985), an antibody-drug conjugate, indicated for the treatment of patients with HER2-positive advanced breast cancer
- In March 2024, Thermo Fisher Scientific launched an advanced single-use bioreactor system with enhanced automation. In January 2025, expanded its biomanufacturing facilities to support large-scale biologics production
- In April 2024, Merck KGaA introduced AI-powered process analytics for optimized biologic production. In February 2025, announced strategic partnerships for mRNA biomanufacturing expansion.
- In May 2024, Danaher Corporation unveiled a next-generation chromatography system for high-purity biologics. In March 2025, acquired a biotech startup specializing in continuous bioprocessing.
